Ctxr stock forecast short interest trends are factored into

Short interest trends are factored into the CTXR stock forecast. Declines in short positions over the past month may reduce downside pressure, opening space for upside moves if positive trial updates emerge. Even though its cash burn relative to its market cap makes us a little nervous, we are compelled to mention that we thought Citius Pharmaceuticals' cash burn reduction was relatively promising. Even though we don't think it has a problem with its cash burn, the analysis we've done in this article does suggest that shareholders should give some careful thought to the potential cost of raising more money in the future. Separately, we looked at different risks affecting the company and spotted 2 warning signs for Citius Pharmaceuticals (of which 1 shouldn't be ignored!) you should know about. These comments back up Thompson’s Buy rating on the stock, and his price target, set at $200, implies an upside of 47% on the one-year horizon. (To watch Thompson’s track record, click here ) CTXR stock forecast reflects sector-relative strength, with the stock outperforming comparable biotech peers over the past two weeks. Relative strength index metrics suggest continued capital rotation into higher beta names.